BEVERLY HILLS, Calif., November 8, 2021 / PRNewswire / – GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical-stage immuno-oncology company focused on the development of innovative therapies based on the natural killer cell activator (NK ) Company’s exclusive tri-specific, Tricycle® platform, today announced a restructuring of its management team. Sir. Antoine Cataldo, Chairman and Chief Executive Officer and Mr. Michael handelman, the CFO will both pursue other interests. The Board appointed Dr. Gregory Beurk as interim CEO, and Dr. Gavin Choy as interim CFO. Michael breen assumed the role of Executive Chairman of the Board, Chairman of the Audit Committee and will oversee the transition. The Board of Directors has initiated a search process to identify individuals for permanent positions for both CEO and CFO roles.
“On behalf of the entire Board of Directors, we would like to express our sincere appreciation to Tony and Michael for their dedicated service and strategic advice in positioning GTB to enter its next phase of growth,” commented Mr. . Michael breen, Executive Chairman of the Board of Directors of GT Biopharma. “Tony has been instrumental in laying the groundwork and building the supporting leadership team as we now embark on the transition to a clinical-stage development company with a broad portfolio of advancing assets. quickly to the clinic as the search for a permanent CEO and CFO is underway. ”
Dr. Gregory Beurk said, “I am honored to take on the role of Interim CEO during this critical time for the company. With a strong leadership team already in place spanning the preclinical, clinical, regulatory and manufacturing areas, as well as a very supportive board of directors with proven industry leaders, I believe we are well positioned to move the whole thing forward. of the TriKE® platform for commercialization, global and regional partnerships and the transformation of the oncology landscape by developing the immunotherapies of tomorrow. “
In addition to the promotion of Dr. Berk to President of R&D and CMO announced in August, GT Biopharma previously appointed Dr. Gavin Choy as Director of Clinical Development in June. Dr Choy received his doctorate in pharmacy from University of Southern California and completed residency training at the US Department of Veterans Affairs. Dr Choy also holds a Masters of Business Administration with a focus on health care from the University of California, Irvine, Paul Merage School work. Dr Choy has over 20 years of experience in the pharmaceutical and biotech industry and has held a variety of leadership positions including COO at Apollomics, Inc. as well as President, CG Pharmaceuticals, Inc.
GTB also appointed Stacy’s Grass, MPH, MBA as Senior Vice President, Portfolio Management and Dr. Leslie Bransfield as vice president of chemistry, manufacturing and control (CMC) and pharmaceutical sciences. Ms. Herb and Dr. Bransfield will be instrumental in working with internal stakeholders and external collaborators to advance GTB’s asset pipeline in the clinic.
Ms. Herb has over 20 years of biotechnology experience in a range of roles including business development, strategy, sales, marketing, research and project leadership. Ms. Herb was previously Senior Vice President, Global Project Leadership at Celularity Inc., where she managed the company’s portfolio, including the MSC, NK and CAR-T cell therapy programs. During her tenure, she facilitated several successful IND submissions, led corporate alliance activities, and established strategy and partnerships across the company’s program portfolio. Prior to Celularity, Ms. Herb held various positions in strategy, business development, research, sales and marketing with increasing responsibilities at Celgene Corporation and Wyeth-Ayerst. Ms Herb holds a Masters of Public Health from The Johns Hopkins University and an MBA from The University of houston.
Dr Bransfield has over 10 years of experience in drug development in the biopharmaceutical industry, working on therapeutics from preclinical stage to phase 3 and has held various leadership positions including that of executive director of the program and Data Analytics at Synspira Therapeutics and Director of Analytics Development at Allena. Pharmaceuticals where she successfully managed technical programs, IND enabling studies and CMC regulatory strategies. Dr Bransfield graduated with a bachelor’s degree in chemistry from Lake Superior State University, obtained a doctorate. in chemistry Johns Hopkins University and completed his postdoctoral fellowship at the National Institute of Standards and Technology.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutics based on our proprietary TriKE® NK cell engagement platform. Our TriKE® is designed to harness and enhance the cancer killing abilities of natural killer cells in a patient’s immune system. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota continue the development and commercialization of therapies using TriKE® Technology. For more information, please visit gtbiopharma.com.
This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict, including statements regarding the potential acquisition, the likelihood of closing the potential transaction, our clinical direction and our current and proposed trials. Words and phrases that reflect optimism, satisfaction or disappointment with current prospects, as well as words such as “believes”, “hopes”, “intends”, “believes”, “hopes”, “plans” “,” Plans “,” foresees “and their variations, or use of the future, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Our forward-looking statements do not constitute a guarantee of performance, and actual results could differ materially from those contained or expressed by such statements. When evaluating all such statements, we urge you to specifically consider the various risk factors identified in our annual report on Form 10-K for the year ended. December 31, 2020, our subsequent current reports on Form 8-K, our quarterly report on Form 10-Q for the quarter ended June 30, 2021, and our other documents filed with the Securities and Exchange Commission, each of which could cause actual results to differ materially from those shown in our forward-looking statements.
Our forward-looking statements reflect our current views regarding future events and are based on current financial, economic, scientific and competitive data and information available on current business plans. You should not place undue reliance on our forward-looking statements, which are subject to risks and uncertainties relating to, among other things: (i) the sufficiency of our cash position and our continued ability to raise additional capital to fund our operations, (ii) our ability to complete planned clinical trials, or meet FDA requirements for safety and efficacy, (iii) our ability to identify patients for enrollment in our clinical trials in a timely manner , (iv) our ability to achieve marketable product approval, (v) the design, implementation and conduct of clinical trials, (vii) the results of our clinical trials, including the possibility of adverse clinical trial results, (vii) the market and commercialization of any product that is approved, (viii) the existence or development of treatments that are considered by healthcare professionals or patients s as superior to our products, (ix) regulatory initiatives, compliance with government regulations and regulatory approval process and social conditions, and (x) various other matters, many of which are beyond our control. Should one or more of these risks or uncertainties develop, or if the underlying assumptions prove to be incorrect, actual results could differ materially and adversely from those anticipated, believed, estimated or otherwise indicated by our forward-looking statements.
We intend that all forward-looking statements made in this press release be subject to the safe harbor protection of federal securities laws in accordance with Section 27A of the Securities Act, to the extent applicable. Except as required by law, we assume no responsibility to update these forward-looking statements to reflect events or circumstances that occur after the date of this press release. In addition, we assume no responsibility for informing you of the occurrence of unforeseen events that could cause actual results to differ from those expressed or implied by these forward-looking statements.
Tricycle® is a registered trademark owned by GT Biopharma, Inc.
Corey davis, Ph.D.
SOURCE GT Biopharma, Inc.